ICON (ICLR) Q3 2026 Earnings Call Transcript

ICON (ICLR) reported Q3 2026 earnings with adjusted EBITDA of $337M, adjusted EPS of $2.66, and $300M in free cash flow. Revenue was $2B, down 2.9% YoY. Gross business wins rose 27% YoY, and net business wins hit a record $3.15B. The company highlighted strong performance in large pharma, midsized pharma, and biotech sectors, along with improvements in gross margin and cash generation.

Original reporting
Published Oct 28, 2026, 3:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 3:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ICON (ICLR) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ICLRBullishHigh
01

Why it matters

Earnings beat expectations on margin and cash flow, likely prompting short‑term buying pressure.

02

Market read

First disclosure of ICON's Q3 2026 earnings provides fresh data for traders; the combination of strong cash flow and a sizable buyback creates a bullish catalyst.

03

What to watch

Potential impact of the Symphony divestiture on future revenue mix and integration costs.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

ICON plc reported its Q3 2026 results, highlighting cash generation, margin expansion, and a $400M share repurchase.

Company-level read

Ticker impact

$ICLRBullishHigh confidence
Context

Q3 2026 earnings disclosed adjusted EBITDA $337M, EPS $2.66, revenue just over $2B and a $400M share repurchase.

Expected impact

likely modest upside as investors price in strong cash flow and share repurchase.

Evidence & confidence

First report of earnings with better-than-expected margins and a large buyback typically supports the stock.

Market effects

Positive for the CRO/clinical research services sector, reinforcing demand trends.

Supports broader US healthcare services sentiment.

Limited to investors tracking mid‑cap pharma services firms.

Counterpoint

If revenue decline continues, the buyback may be seen as a defensive move, limiting upside.

Key entities

  • Barry Balfe

    CEO of ICON who presented the earnings call.

  • Nigel Clerkin

    CFO who detailed the financial metrics.

Related articles

$ICLRMed

Icon PLC (ICLR) (Q3 2026) Earnings Call Highlights: Record

Icon PLC (ICLR) reported Q3 2026 revenue of $2B, down 2.9% YoY. Direct fee revenue growth remains modest, and cancellations are slightly above average. Gross margin improved 90 bps sequentially, and adjusted EBITDA margin rose to 16.6%. The company expects Q4 SG&A expenses to increase and faces ongoing pricing pressure. Management anticipates mid-single-digit revenue growth and higher single-digit earnings growth in 2027, with formal guidance to be provided in Q4.

$ICLRHighAI 8/10

ICLR Stock Jumps As Guidance And Backlog Impress Wall Street

ICON plc (NASDAQ: ICLR) stock rose 16.39% on October 28, 2026, after beating Q3 earnings expectations and raising 2026 revenue guidance to $8.10B–$8.20B. The company reported adjusted EPS of $2.66 and revenue of $2.02B, with a record backlog and $400M in share repurchases. Analysts have mixed reactions, with upgrades from Bank of America and RBC, while UBS remains cautious.

$ICLRHighAI 8/10

ICLR Stock Jumps As Earnings Beat And Guidance Rise

ICON plc (ICLR) stock rose 11.54% after Q3 earnings beat expectations, with revenue of $2.02B and EPS of $2.66. The company raised full-year guidance, citing strong demand and a record backlog. Analysts have mixed views, with some upgrading and others warning of risks. ICLR trades at a premium multiple, with technical indicators showing strong momentum.